Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.

Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.

  • Post by:
  • 17 April 2019
  • Comments off
Categories:

Participating Institutions

The University of Queensland
The University of Sydney
Australian National University
Monash University
Queensland University of Technology
Edith Cowan University
CSIRO

International Partners

Boston Children’s Hospital, Harvard
University of Washington
University of Tokyo
Massachusetts Institute of Technology
University of Illinois at Urbana-Champaign
University of Southampton

Twitter
YouTube